This Week’s Life Science Headlines

        Litigation
Continue reading...

Last Week’s Important Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

Pennsylvania Supreme Court Opens Door for Negligent Design Claims Against Pharmaceutical Manufacturers

In a decision with significant potential ramifications, the Pennsylvania Supreme Court has issued a ruling that pharmaceutical companies can be held liable for negligence in the design and marketing of drugs, regardless of claims that the drugs had been properly labeled and tested, as well as approved by the U.S. Food and Drug Administration. The ruling, announced January 22nd, upholds an intermediate appellate court decision against a Pfizer, Inc. subsidiary in a wrongful death action involving the diet drug Redux. In its 4-2 decision, the…
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

Despite Reported Risks, Side Effects and Threatened Litigation, Crestor Top Selling Drug

According to a report by the research firm IMS Health, (free membership login required) new prescriptions and refills for Crestor, a drug used to lower cholesterol, exceeded all other prescribed drugs in the United States between October 2012 and September 2013. Crestor (rosuvastatin), like Lipitor (atorvastatin) is widely-used to lower cholesterol and belongs  to a family of drugs called “statins.” Among the best-selling drugs in the United States, statins use the liver to block the body’s creation of cholesterol, which is a key contributor…
Continue reading...

First New York Court Rejects Controversial Drug Developer Liability Rule

In a controversial 2008 decision in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (Cal. Ct. App. 2008), a California Court of Appeals held defendant drug developer, Wyeth, Inc., liable for inadequate warnings in connection with the plaintiff’s use of a competitor’s generic version of the gastrointestinal reflux drug Reglan. The court in Conte held “the common law duty to use due care owed by a name-brand prescription drug manufacturer when providing product warnings extends not only to consumers of its own product,…
Continue reading...